Visszatérés

Szolgáltatásink az alábbi országokban elérhetőek

Corporate

Európa:

Zászló Albánia Albánia Zászló Bosznia Herzegovina Bosznia Herzegovina Zászló Bulgária Bulgária Zászló Horvátország Horvátország Zászló Ciprus Ciprus Zászló Montenegró Montenegró Zászló Cseh Köztársaság Cseh Köztársaság Zászló Dánia Dánia Zászló Észtország Észtország Zászló Spanyolország Spanyolország Zászló Koszovó Koszovó Zászló Litvánia Litvánia Zászló Lettország Lettország Zászló Luxemburg Luxemburg Zászló Macedónia Macedónia Zászló Németország Németország Zászló Lengyelország  Lengyelország  Zászló Portugália Portugália Zászló Románia Románia Zászló Szerbia Szerbia Zászló Szlovákia Szlovákia Zászló Szlovénia Szlovénia Zászló Svájc Svájc Zászló Svédország Svédország Zászló Törökország Törökország Zászló Magyarország Magyarország Zászló Egyesült Királyság Egyesült Királyság Zászló Olaszország Olaszország

Ázsia:

Zászló UAE UAE Zászló Hong-Kong Hong-Kong Zászló Kuvait Kuvait Zászló Libanon Libanon

Afrika:

Zászló Dél-Afrika Dél-Afrika
Visszahívást kérek

Szeretne többet megtudni szolgáltasainkról?

Töltse ki az alábbi regisztrációs felületet és kollégáink hamarosan felveszik önnel a kapcsolatot, hogy válaszoljanak minden felmerülő kérdésére

    "Adatait semmilyen körülmények között nem tesszük harmadik fél számára hozzáférhetővé.

    Obraz

    Életmentő
    transzplantációk listája

    A Famicord csoport laboratóriumaiból kezelésre kiadott minták listája.

    Obraz
    Lp. Őssejt forrás Forrás típusa Diagnózis Érintett szakterület Kezelés éve Terápia Ország Páciens életkora
    401 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 26
    402 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 40
    403 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 68
    404 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
    405 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms Hematology 2026 Standard Therapy Spain 65
    406 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 63
    407 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 58
    408 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 44
    409 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 61
    410 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 54
    411 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Poland 11
    412 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 64
    413 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 64
    414 Apheresis autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 32
    415 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
    416 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 54
    417 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
    418 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 72
    419 Apheresis autologous Peripheral T-cell Lymphoma Hematology 2026 Standard Therapy Germany 56
    420 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    421 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    422 Apheresis autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 47
    423 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    424 Apheresis allogeneic Vexas-Syndrome with UBA1-Mutation Hematology 2026 Standard Therapy Germany 67
    425 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 27
    426 Apheresis allogeneic Primary Myelofibrosis PMF Hematology 2026 Standard Therapy Poland 57
    427 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 48
    428 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 67
    429 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 42
    430 Apheresis allogeneic MPS-I: Hurler Syndrome Hematology 2026 Standard Therapy Russia 1
    431 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 29
    432 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 47
    433 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 66
    434 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 4
    435 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    436 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 63
    437 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Lithuania 40
    438 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 68
    439 Apheresis allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Netherlands 61
    440 Apheresis allogeneic Acute Lymphoblastic leukemia Hematology 2026 Standard Therapy Germany 21
    441 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 72
    442 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 36
    443 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
    444 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 63
    445 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 54
    446 Apheresis allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 54
    447 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 76
    448 Apheresis allogeneic Myelodysplastic Disorders Hematology 2026 Standard Therapy France 73
    449 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 75
    450 Apheresis allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 47
    451 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 68
    452 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 40
    453 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Macedonia 59
    454 Apheresis allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy Belgium 4
    455 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Australia 13
    456 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
    457 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 38
    458 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Russian Federation 28
    459 Apheresis allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 58
    460 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 54
    461 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
    462 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy United Kingdom 20
    463 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
    464 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 69
    465 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 64
    466 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 56
    467 Apheresis autologous Myeloma Hematology 2026 Standard Therapy Portugal 42
    468 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
    469 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    470 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 71
    471 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    472 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 24
    473 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 67
    474 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 62
    475 Apheresis Autologous Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 43
    476 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 60
    477 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    478 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    479 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
    480 Apheresis Allogeneic Primary Myelopathic Polycythemia Hematology 2026 Standard Therapy Germany 67
    481 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    482 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
    483 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
    484 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 32
    485 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
    486 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
    487 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 42
    488 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 65
    489 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Germany 73
    490 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
    491 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Italy 6
    492 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
    493 Apheresis Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy India 3
    494 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 32
    495 Apheresis Allogeneic Mixed-Phenotype Acute Leukemia Hematology 2026 Standard Therapy Poland 40
    496 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 64
    497 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 58
    498 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
    499 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 45
    500 Apheresis Allogeneic T-cell non-Hodgkin Lymphoma (Mycosis Fungoides) Hematology 2026 Standard Therapy Portugal 43